As neurodegenerative diseases continue to rise globally, researchers are turning to more physiologically relevant preclinical systems to close the translational gap that has long hindered CNS drug development. Alzheimer's disease alone affects more than 40 million people worldwide, and Parkinson's disease remains the second most common neurodegenerative disorder. Yet despite decades of...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek